This listing of claims will replace all prior versions and listings of claims in tRECEIVED application:

OCT 0 8 2003

## Listing of Claims:

TECH CENTER 1600/2900

1-46. (canceled)

- 47. (currently amended) A bispecific antibody comprising a first polypeptide and a second polypeptide, the bispecific antibody comprising:
- (a) the first polypeptide which comprises a first heavy chain variable domain, a first or second light chain variable domain <u>each having three CDR regions</u>, wherein the first and second light chain variable domains have at least 80% 98% amino acid sequence identity and <u>only differ from one another at amino acid positions outside of the CDR regions</u> have at least one CDR region that has the same sequence, and wherein a first binding domain is formed by the first heavy chain variable domain and the first or second light chain variable domain;
- (b) the second polypeptide which comprises a second heavy chain variable domain, the first or the second light chain variable domain, wherein a second binding domain is formed by the second heavy chain variable domain and the first or second light chain variable domain, and wherein the first and second binding domains bind different antigens;
  - (c) the first and second polypeptides dimerize to form a bispecific antibody.
- 48. (new) The bispecific antibody of claim 47, wherein the first polypeptide further comprises a first multimerization domain, and the second polypeptide further

form a bispecific antibody.

- 49. (new) The bispecific antibody of claim 48, wherein the multimerization domains of the first and second polypeptide interact at an amino acid side chain protuberance of one of the first and second polypeptides and an amino acid side chain cavity of the other polypeptide.
- 50. (new) The bispecific antibody of claim 48, further comprising a non-naturally occurring disulfide bond between the first and second polypeptide.
- 51. (new) The bispecific antibody of claim 50, wherein the multimerization domain is a  $C_{\rm H}3$  region of an antibody constant domain.
- 52. (new) A composition comprising the bispecific antibody of claim 47 and a carrier.
- 53. (new) The bispecific antibody of claim 47, wherein the first and second light chain variable domains have identical amino acid sequences.
- 54. (new) A bispecific antibody comprising a first polypeptide and a second polypeptide, the bispecific antibody comprising:
- (a) the first polypeptide which comprises a first heavy chain variable domain, a first multimerization domain, a light chain variable domain, and wherein a first binding domain is formed by the first heavy chain variable domain and said light chain variable domain;
- (b) the second polypeptide which comprises a second heavy chain variable domain, a second multimerization domain, said light chain variable domain, wherein a

different antigens;

(c) the first and second polypeptides dimerize by interaction of the first and second in Atmicia atron to form a hispecific antibod.

- 55. (new) The bispecific antibody of claim 54, wherein the multimerization domains of the first and second polypeptide interact at an amino acid side chain protuberance of one of the first and second polypeptides and an amino acid side chain cavity of the other polypeptide.
- 56. (new) The bispecific antibody of claim 54, further comprising a non-naturally occurring disulfide between the first and second polypeptides.
- 57. (new) The bispecific antibody of claim 56, wherein the multimerization domain is a  $C_{\rm H}3$  region of an antibody contact domain.
- 58. (new) A composition comprising the bispecific antibody of claim 54 and a carrier.
- 59. (new) A bispecific antibody comprising a first polypeptide and a second polypeptide, the bispecific antibody comprising:
- (a) a common variable light chain domain that has at least 98% sequence identity to a first and a second variable light chain domain of a first and a second antibody;
- (b) the first polypeptide which comprises a first heavy chain variable domain from the first antibody and a first multimerization domain comprising a first  $C_H3$  domain;
- (c) the second polypeptide which comprises a second heavy chain variable domain from the second antibody and a second multimerization domain comprising a second  $C_{\rm H}3$  domain;

second heavy chain variable domain and the common light chain variable domain, and the first and second multimerization domains interact to form a bispecific antibody.

- 60. (new) The bispecific antibody of claim 59, wherein the common light chain domain has 100% sequence identity to the first and second variable light chain domain.
- 61. (new) The bispecific antibody of claim 59, wherein the first multimerization domain has a protuberance and the second multimerization domain has a cavity and the first and second multimerization domains interact via fitting of the protuberance into the cavity.
- 62. (new) The bispecific antibody of claim 61, further comprising an non-naturally occurring disulfide bond between the first and second polypeptide.
- 63. (new) A composition comprising the bispecific antibody of claim 59 and a carrier.

5